Thursday, 8 August 2013

Netherlands Pharmaceuticals and Healthcare Report Q4 2013: Business Monitor International Market Research Reports

Business Monitor International Market Research Reports
Market Reports Online XML Feed 
Keep More Customers

Increase customer retention and trial conversion rates by 30% with data you already collect.
From our sponsors
Netherlands Pharmaceuticals and Healthcare Report Q4 2013
Aug 7th 2013, 00:00

Price: $ 1295  

BMI View: We maintain our subdued outlook on the Dutch pharmaceutical and healthcare sector for the remainder of 2013 and looking forward into 2014. With further essential structural reform to the public sector on the horizon, leading to excessive budget deficits, we see economic recovery being put on hold. We therefore do not expect the pharmaceutical industry to return to positive growth until 2016 at the earliest. The Dutch on average spend 14% less on medicines than the rest of Western Europe, and uptake of generic medicines, encouraged by patent expiries and insurers' preference policies, will result in continuing negative pressures on volume consumption and prices of medicines. Headline Expenditure Projections ? Pharmaceuticals: EUR6.88bn (US$8.74bn) in 2012 to EUR6.81bn (US$9.06bn) in ...

Complete report details with Table of Contents and more @ http://www.marketreportsonline.com/266778.html

Delicious Digg Evernote Facebook Google Bookmarks Google Plus LinkedIn StumbleUpon Tumblr Twitter
You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

No comments:

Post a Comment